Food and Drug Administration
AM Session
Abbot Laboratory Briefing
Material
The statements
contained in this document(s) are not those of the FDA, and FDA does not
necessarily agree with these statements.
FDA has not made a final determination about the issues to be discussed at
the Advisory Committee meeting.
Xinlay™ (atrasentan hydrochloride) capsules briefing material
Food and
Drug Administration
Portions of these documents may have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. §552). These redacted portions will appear as white space on the screen or on the printed page.
FDA Xinlay™ Statistical Review
PM Session
OSI Pharmaceuticals Inc.
The statements contained in this
document(s) are not those of the FDA, and FDA does not necessarily agree with
these statements.
FDA has not made a final determination about the issues to be discussed at
the Advisory Committee meeting.
Tarceva™ (erlotinib) tablets briefing material
Food and
Drug Administration
Disclaimer
Portions of these documents
may have been determined to be exempt from disclosure under the Freedom of
Information Act (the FOIA) (5 U.S.C. §552).
These redacted portions will appear
as white space on the screen or on the printed page.